The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Lignende værker

• The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
  af: Dintsios, C. M., et al.
  Udgivet: (2020)
• Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept
  af: Wettstein, Dominik J., et al.
  Udgivet: (2021)
• Predictors of negotiated prices for new drugs in Germany
  af: Gandjour, Afschin, et al.
  Udgivet: (2020)
• The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
  af: Wettstein, Dominik J., et al.
  Udgivet: (2020)
• Health technology assessment and reimbursement of pharmaceuticals in Italy
  af: F. V. Gorkavenko, et al.
  Udgivet: (2019-07-01)